News

January 19, 2022

Second Genome Appoints Joseph Dal Porto, Ph.D., as Chief Scientific Officer

December 20, 2021

Second Genome Granted U.S. Patent for Proteins for the Treatment or Prevention of Epithelial Barrier Function Disorders

November 18, 2021

Second Genome Presents Preclinical Data at Crohn’s & Colitis Foundation’s® IBD Innovate Conference for Potential First in Class Mucosal Healing Therapeutic SG-5-00455

November 12, 2021

Second Genome Presents Preclinical Data at SITC 2021 Demonstrating that a CXCR3-Positive Allosteric Modulator, SG-3-00802, Targets a Key Mechanism Required for Efficacious Immunotherapy

November 11, 2021

Second Genome Presents Preclinical Data Highlighting Potential Therapeutic Implications of Altered Gut Microbiome and Metabolites in Autism Spectrum Disorder Model and Parkinson’s Disease at The Society for Neuroscience Annual Meeting

See All News